Compare ANDE & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANDE | CLDX |
|---|---|---|
| Founded | 1947 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | N/A | 2008 |
| Metric | ANDE | CLDX |
|---|---|---|
| Price | $53.97 | $27.36 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $58.33 | $43.80 |
| AVG Volume (30 Days) | 311.3K | ★ 775.5K |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | ★ 1.48% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.13 | N/A |
| Revenue | ★ $11,595,817,000.00 | $2,599,000.00 |
| Revenue This Year | $6.47 | N/A |
| Revenue Next Year | $3.36 | $19.70 |
| P/E Ratio | $25.34 | ★ N/A |
| Revenue Growth | ★ 2.19 | N/A |
| 52 Week Low | $31.03 | $14.40 |
| 52 Week High | $54.38 | $30.50 |
| Indicator | ANDE | CLDX |
|---|---|---|
| Relative Strength Index (RSI) | 67.53 | 52.62 |
| Support Level | $49.14 | $27.51 |
| Resistance Level | $53.32 | $28.79 |
| Average True Range (ATR) | 1.43 | 1.34 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 93.32 | 43.25 |
Andersons Inc is a diversified company with its main focus in the agriculture sector. Its operations are segmented into Trade, Renewables, and Nutrient & Industrial. The Trade segment, which generates the majority of the revenue, is engaged in the movement of physical commodities such as whole grains, grain products, feed ingredients, and domestic fuel products, among other agricultural commodities. Geographically, the company generates the majority of its revenue from the United States and the rest from Canada, Mexico, Egypt, Switzerland, and other markets.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.